CD8A and cancer: Despite the safety and clinical feasibility of vaccinating cancer patients with either WT1A or WT1B peptide, it is still unclear whether the alternate WT1B epitope is indeed a more favorable vaccine candidate in terms of its ability to induce or expand an effective polyfunctional WT1-specific CD8+ T-cell response in cancer patients.